Cancer Molecular Pathology of School of Medicine and Dentistry, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
Pathology Queensland, Gold Coast University Hospital, Southport, QLD, Australia.
Methods Mol Biol. 2022;2534:175-195. doi: 10.1007/978-1-0716-2505-7_13.
Immunohistochemistry (IHC) is an economic and precise method to localize the presence of specific protein at cellular level in tissue. Although many papillary thyroid carcinomas do not require IHC to render a diagnosis, there are certain scenarios in which IHC are important. The major diagnostic applications of IHC include confirmation of papillary thyroid carcinoma in sites other than the thyroid, distinguish papillary thyroid carcinoma from other primary thyroid neoplasms in thyroid, and identify papillary thyroid carcinoma from secondary tumors to the thyroid. At research level, IHC could help identify prognostic information, identify underlying genetic alterations, and predict response to treatment in papillary thyroid carcinoma. The understanding of principle and recent advances in IHC will improve the diagnosis and management of patients with thyroid lesions including papillary thyroid carcinoma.
免疫组织化学（IHC）是一种经济而精确的方法，可在组织的细胞水平上定位特定蛋白质的存在。尽管许多甲状腺乳头状癌不需要免疫组化来做出诊断，但在某些情况下免疫组化是很重要的。免疫组化的主要诊断应用包括在甲状腺以外的部位确认甲状腺乳头状癌，在甲状腺中区分甲状腺乳头状癌与其他原发性甲状腺肿瘤，以及将甲状腺的继发性肿瘤与甲状腺乳头状癌区分开来。在研究水平上，免疫组化可以帮助确定预后信息，识别潜在的遗传改变，并预测甲状腺乳头状癌的治疗反应。对免疫组化原理和最新进展的了解将改善包括甲状腺乳头状癌在内的甲状腺病变患者的诊断和治疗。
